Abstract 9P
Background
Breast cancer is identified as a leading cancer in Kyrgyz females. Poor diagnostic approaches lead to high rate of advanced breast cancer cases and consequently to a high mortality rate. Genetic testing is a promising method of prevention and early diagnosis of breast cancer.
Methods
This was a case-control study of 201 women of the Kyrgyz ethnic group with a morphologically verified breast cancer (N=99) and 102 controls age-matched with BC cases. The mean age of the patients was 48 years (minimum 24, maximum 74, STD=9.83). The extraction of DNA was carried out from venous blood. The genotyping was performed by using restriction fragment length polymorphism assay.
Results
Genotype CT of the polymorphic variant V353A HMMR gene has been defined as protective factor and decreases the risk of developing of breast cancer in the Kyrgyz population (OR=0,481, 95%CI 0,272 – 0,850, р=0,011). As well as combinations of the allele 194Trp (XRCC1 Arg194Trp) and genotype СТ (HMMR V353A) (OR=0,302, [95% CI 0,128-0,713], р=0,005), CT/TT (OR=0,459, 95% CI [0,259-0,814], р=0,007) of HMMR V353A and Palb2 T1100T (3300T>G)polymorphisms, CT/GG (OR=0,546, 95% CI [0,298-0,999], р=0,048) of HMMR V353A and TNF aG3080A polymorphisms are associated with decreased risk of developing of breast cancer in the Kyrgyz ethnic group. Furthermore, the allele 194Trp is associated with late age of diagnosis of breast cancer when comparing to 194Arg allele of XRCC1 gene (p=0,017), more often occurs in postmenopausal women (p=0,005) and in women with high BMI (>25) (p=0,003).
Conclusions
The above genotypes may be used as markers for evaluation of the risk of breast cancer in the Kyrgyz ethnic group.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
117P - Short-term and long-term outcomes of hepatectomy combined with intraoperative radiofrequency ablation for multiple colorectal liver metastases: A propensity score matching study
Presenter: Wenbai Huang
Session: Poster display session
Resources:
Abstract
119P - The impacts of dose-time-fractionation schedules on pathological complete response rate (pCR) and local recurrence (LR)
Presenter: Fu Jin
Session: Poster display session
Resources:
Abstract
120P - Platelet to lymphocyte ratio is associated with tumour localization and outcomes in patients with metastatic colorectal cancer
Presenter: Ahmet Bilici
Session: Poster display session
Resources:
Abstract
121P - Meta-analysis of three-dimensional versus two-dimensional laparoscopic surgery for rectal cancer
Presenter: Laiyuan Li
Session: Poster display session
Resources:
Abstract
127P - Outcomes based on albumin‐bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
Presenter: Stephen Chan
Session: Poster display session
Resources:
Abstract
128P - Tislelizumab in combination with chemotherapy for Chinese patients (Pts) with gastric/gastroesophageal junction cancer (GC/GEJC) or esophageal squamous cell carcinoma (ESCC)
Presenter: Yuxian Bai
Session: Poster display session
Resources:
Abstract
129P - Monitoring patient-specific mutation in ctDNA and CTC for tumour response evaluation after neoadjuvant chemotherapy in advanced gastric adenocarcinoma (NCT03425058)
Presenter: Tao Fu
Session: Poster display session
Resources:
Abstract
130P - Development of a liver cancer risk prediction model for the general population in china: A potential tool for screening
Presenter: Xiaoshuang Feng
Session: Poster display session
Resources:
Abstract
131P - Cabozantinib in Asian patients with hepatocellular carcinoma and other solid tumours: Population pharmacokinetics analysis
Presenter: Chih-Hung Hsu
Session: Poster display session
Resources:
Abstract
132P - Liposomal irinotecan (nal-IRI) plus 5-fluorouracil/levoleucovorin (5 FU/LV) vs 5-FU/LV in Japanese patients (pts) with gemcitabine-refractory metastatic pancreatic cancer (mPAC)
Presenter: Tatsuya Ioka
Session: Poster display session
Resources:
Abstract